Cardio-oncology & otherCohort study

Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant

JAMA CardiolPublished

  • Retrospective cohort study
  • single-centre

Authors' conclusion

CHIP was significantly and independently associated with risk of CVD in patients with MM undergoing HCT and may serve as a novel biologically plausible biomarker for CVD in this cohort. Patients with MM and both CHIP and cardiovascular risk factors had an exceptionally high risk of CVD.

Study context

Population
Patients with multiple myeloma undergoing first autologous hematopoietic cell transplant (HCT), City of Hope, 2010–2016
Participants
1,036 patients
Exposure
Clonal hematopoiesis of indeterminate potential (CHIP) vs no CHIP
  • CHIPn = 201
Outcome
Cumulative incidence and risk of de novo CVD (HF, CAD or stroke) after HCT
Follow-up
5 years

Main finding

CVD

Hazard ratio

2.72

95% CI 1.70–4.39

P < 0.001

By group

CHIP vs No CHIP
HR 2.72 (95% CI 1.70–4.39); P < 0.001

As reported in the abstract

Observational data: associations, not effects.

Further findings

OutcomeValuesHR (95% CI)
Individual CVD outcomes — CHIP vs No CHIP · HF · multivariable model4.02 (2.32–6.98)
Individual CVD outcomes — CHIP vs No CHIP · CAD · multivariable model2.22 (1.06–4.63)
Individual CVD outcomes — CHIP vs No CHIP · stroke · multivariable model3.02 (1.07–8.52)
OutcomeValuesEstimate
CVD, ≥2 CHIP variants · 5 years≥2 variants 25.6%

Cardiovascular disease (CVD) with CHIP plus preexisting hypertension or dyslipidemia

CHIP + hypertension: nearly 7-fold increased risk; CHIP + dyslipidemia: 4-fold (reference: no CHIP, no hypertension, or dyslipidemia)

Original publication

Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant. JAMA Cardiol. Published 1 January 2024. doi:10.1001/jamacardio.2023.4105

Summarised from the published abstract; every number is checked against it